InnoCare Announces Clearance by the US FDA of Phase II Clinical Trial Using orelabrutinib for the Treatment of Multiple Sclerosis
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today the Investigational New Drug…